Participated · Series A · Oct 2023

Cataya is a synthetic biology company focused on biomanufacturing chemical and biochemical products. Its pipeline targets high-value ingredient molecules with applications across food, cosmetics, and general consumer goods. Founded in 2021, the company is led by industry veterans and CEO Dr. Lishan Zhao. Cataya has completed three financing rounds within a single year, reflecting rapid development and market potential. Proceeds from the recent round will fund pipeline R&D, talent recruitment, and construction of manufacturing facilities. The company plans to establish research and business units in the US and Japan in the future. Eight Roads noted support will come from both their technology and healthcare teams to back Cataya’s product-driven R&D platforms.

Participated · Series B · Jun 2022

Mojia Biotech is a product-focused bio-manufacturing company led by Ansen Chiew that produces food ingredients and chemical materials using renewable carbon sources and green processes. The company has developed the Viridimin™ brand of Vitamin B5 and aims to commercialize it as an animal-feed additive. Its second targeted product line is the Aliphane™ series of biopolymer products, intended for coating and adhesive applications. Mojia plans to scale up manufacturing capacity for the Aliphane series while advancing its broader product pipeline. The company also intends to expand its global R&D capabilities to support commercialization and product development efforts.

Participated · Series B · May 2022

Spun out of the University of Oxford in 2017, Moa Technology operates proprietary discovery platforms that have screened over 900,000 compounds and discovered more than 80 novel mode of action areas capable of breaking weed resistance. Several of its advanced programmes are now in their third year of international field trials, and in 2025 the company disclosed a new category of non-herbicidal products called Moa Amplifiers. Moa has established R&D collaborations with major industry partners including Nufarm, Gowan, Certis Belchim and Corteva Agriscience to progress commercial applications. The company plans to use its Series C proceeds and partner payments to push three lead programmes closer to commercialisation, expand its early-stage pipeline, and continue development of the Moa Amplifiers strategy. Its platform and commercial partnerships are positioned to support further industry deals and field deployment of its discoveries.

Participated · Series A · Feb 2022

Next Gen Foods is a Singapore-based alternative protein company and creator of TiNDLE, a plant-based chicken alternative made from a proprietary blend of plant-based ingredients. The company develops components, ingredients and recipes while using an asset-light model that contracts production to manufacturing partners to scale internationally. TiNDLE is being launched through chef and restaurant partnerships and is available in cities including San Francisco, Los Angeles, Napa, New York and Philadelphia, and in markets such as Singapore, Hong Kong, Macau, Abu Dhabi, Kuala Lumpur, Dubai and Amsterdam. U.S. distribution is expanding (available via DOT Foods, FoodServiceDirect.com and Cheetah in the Bay Area) and the company plans to push TiNDLE into all 50 states. Next Gen Foods is building an R&D center in Singapore in partnership with the Food Tech Innovation Center and intends to hire protein scientists and food technologists in Singapore, Europe and the U.S. It plans to expand TiNDLE’s product roster (eg, nuggets or tenders) and eventually introduce alternatives to other animal proteins, though broader protein launches are unlikely within the next two years. Next Gen Foods produces TiNDLE, a plant-based chicken alternative formulated with a proprietary blend of plant-based fats, including sunflower oils and natural flavors to replicate chicken aroma, browning and texture. TiNDLE is GMO- and cholesterol-free and has launched in more than 70 restaurant locations across Singapore, Hong Kong and Macau. The company follows an asset-light business model and plans to enter the U.S. over the next 12 months via foodservice partnerships, later expanding into other distribution channels such as retail. Next Gen will use part of the recent funding to hire about 50 U.S.-based roles across research and development, sales, supply chain, finance and marketing. Leadership changes announced alongside the fundraise include co-founder Timo Recker moving to chairman, founder Andre Menezes becoming CEO, and former Temasek director Rohit Bhattacharya joining as CFO. Next Gen Foods is a Singapore-based plant-based protein company preparing to launch its first brand, TiNDLE, which will offer a variety of plant-based 'chicken' products. The startup raised $10 million in a seed round, a deal the article says breaks the global record for the largest seed round by a plant-based startup. Next Gen will use the funds to launch TiNDLE in Singapore and other Asian cities, hire its first US employee, and fund further product research. The company plans to be on track for a Series A within the next two years. The article places the raise and product roadmap in the context of growing plant-based demand and market projections for the sector.

Participated · Series A · Feb 2022

TiNDLE is a plant-based chicken product developed by Next Gen Foods using a blend of soy, wheat gluten, wheat starch, coconut oil, oat fiber, methylcellulose and the company’s trademarked Lipi™ sunflower-oil blend to mimic chicken fat. The product debuted less than 18 months ago and is already available in over 200 restaurants across six cities and via U.S. home delivery on Goldbelly. Next Gen emphasizes TiNDLE’s flexible format for chefs and culinary applications as a key differentiator. The company cites substantial sustainability benefits versus conventional chicken—74% less land, 88% fewer greenhouse gas emissions and 82% less water. Proceeds will be used to expand distribution across all 50 U.S. states, scale international R&D and complete a flagship research hub in Singapore slated to open later this year. The company is hiring protein scientists and food-tech experts to support its global growth. TiNDLE is a plant-based chicken product line launched by Next Gen in early 2021 and sold in more than 70 restaurants across Singapore, Hong Kong and Macau. Its first product, TiNDLE Thy, was developed with chefs to replicate chicken thigh flavor and versatility and is positioned as high-protein, high-fiber, low-carb, No-GMO and naturally zero cholesterol. The brand has secured validation through partnerships with noted chefs and Michelin-starred restaurants and operates an asset-light distribution model. TiNDLE plans international expansion, including a US market entry within 12 months, continued rollouts across Asia-Pacific and the Middle East, and further expansion into Europe. The company will establish an R&D center in Singapore, diversify its product range, and hire more than 50 US staff in R&D, sales, supply chain, finance and marketing to support the launch.